• 30+ years of diverse encompassing pharmaceutical investment and research, hospital management, and real estate development, demonstrating versatility across industries

• Demonstrated leadership in botanical and chemical drug research and development within the pharmaceutical sector, driving innovation and scientific breakthroughs

• Former President of Duraviva Pharma Inc., where responsibilities included guiding the company's strategic direction and fostering growth through market expansion and product development

• Bachelor's degree from Northeast Normal University 

• 20+ years of experience in the pharmaceutical industry with expertise in drug substance and drug product development from preclinical through commercialization

• Successful track record in one NDA submission (KarXT) and six ANDA/505(b)(2) NDA submissions, with four products on the market including Cobenfy, Buprenorphine products 

• Deep expertise in analytical method development, validation, transfer, specifications, and supporting clinical trials, registration, and PPQ 

• Extensive experience with analytical techniques including HPLC, GC, CE, IC, KF, particle size, FTIR, TGA/DSC, UV/vis, LC/QDa, fluorescence and dissolution 

• Successfully led 20+ analytical development projects and set up two GMP analytical labs 

• Postdoctoral research fellow at Northeastern University and Biogen, developing CE methods 

• PhD in Analytical Chemistry, University of York, UK 

• MSc in Environmental Analytical Chemistry and BSc in Organic Chemistry, Nanjing University, China 

Dr. Helen Hsu is a Medical Executive (M.D.) with 30 years of experience in drug discovery, clinical research and commercialization.  Her leadership in Pharmaceutical /Biotech industry involves the whole life cycle management from preclinical R&D, translational research, to clinical program development, Medical Affairs and business development. Helen has spearheaded IND / NDA submissions and monitored global Phase I-V clinical trials in multiple therapeutic areas such as Oncology/Hematology, Neurology, Cardiology, GI, Women’s Health and Pediatric studies. Her broad experience spanning big pharma (GSK, Novartis, BI) to biotech (Epizyme, Ipsen) and CRO (Pharmaron), plus her skills in clinical practice and research program strategy are an asset for the Board. 

During Helen’s tenure leading a the research department at a cancer center in the US, and building a research institute at the Harvard Medical School affiliated International Hospital in China, Helen successfully integrated the hospital research program and established a unique pathway for bringing innovative products to cancer patients.

Helen received her Medical Education from Southeast University Medical School followed by clinical practice as an Internist in China. She also completed her graduate studies at MSU and received her post-doctoral trainings in molecular biology and genetic disease from Albert Einstein College of Medicine and NYU Medical School Teaching Hospital in the US.

• 20+ years of experience across leading financial firms including Credit Suisse, Merrill Lynch, PingAn Group, and Fosun Group 

• Co-founded BitDATA Exchange, a regulated digital asset trading platform, and led the development of Fosun's first internet-based alternative financial platform 

• Deep expertise in securitization, structured products, derivatives, fintech, blockchain and AI investments 

• Structured and designed billions of dollars worth of securitized products and provided client-facing research and modeling 

• Managed investment and operating teams, driving investment processes in fintech, blockchain and AI 

• CEO/CIO of a PE/Industrial fund, completing 24 investments totaling 1.13 billion RMB 

• PhD in Finance, University of Alabama 

• BS in Economics, Fudan University 

• 20+ years of experience in executive leadership roles across banking, education, and international business 

• Currently serves as Executive Director & Co-CEO of Citychamp Watch & Jewellery Group and a director of its wholly owned subsidiary Bendera Bank since 2021 

• Manages various risks including management risk, operational risk and liquidity risk as a member of the Risk Management Committee of the Board of Directors 

• Previously served as Vice Chairman of the Board and non-executive director of China Chunlai Education Group from 2020-2021 

• Chairman and CEO of Yuanyin International Limited from 2018-2020, formulating overall strategy and controlling business development risks 

• Bachelor's degree in Economics and Law, Henan University 

• Two Master's degrees from Xiamen University and University of Northumbria